CoChat

ERK1/2 Signaling Pathway in the Release of VEGF from Müller Cells in Diabetes

Ye, Xiaofeng, Ren, Hui, Zhang, Meng, Sun, Zhongcui, Jiang, Alice C., Xu, Gezhi · 2012 · Investigative Opthalmology & Visual Science

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

PURPOSE: Diabetic retinopathy (DR) is one of the most serious complications of diabetes and has become a major blinding eye disease, but its treatment remains unsatisfactory. The ERK1/2 signaling pathway has been shown to participate in regulating secretion of VEGF in DR from our previous studies. The role of VEGF in the development of DR provides a target for treatment. Our present research focuses on Müller cells, a major source of VEGF secretion, to investigate the role of ERK1/2 signaling pathway on regulation of VEGF release in diabetes. METHODS: Immunofluorescence was used to observe the ERK1/2 phosphorylation activity on early diabetic rat retinal Müller cells. Müller cells were stimulated by high glucose in vitro. Western blot and immunohistochemistry were used to determine ERK1/2 signaling pathway expression and phosphorylation. AP-1 DNA binding activity status was monitored by electrophoretic mobility shift assay (EMSA). ELISA and PCR monitored VEGF secretion. Inhibition of ERK1/2 phosphorylation with U0126 was observed for changes in VEGF secretion. RESULTS: Phos-ERK1/2 was expressed on Müller cells early in diabetes. In vitro high glucose stimulation of Müller cells increased VEGF secretion with a peak at 24 hours. An ERK1/2 specific inhibitor, U0126, stopped the phosphorylation of ERK1/2, lowered AP-1 DNA binding activity, and reduced Müller cells secretion of VEGF under high glucose conditions. CONCLUSIONS: ERK1/2 signaling pathway has some role in regulating Müller cells secretion of VEGF in DR. Targeting the ERK1/2 signaling pathway in Müller cells through intervention of the upstream signaling pathway or nuclear transcription factors of VEGF secretion could be a type of anti-VEGF treatment for DR.

Overview

Integrity signals

Registry

Crossref · 10.1167/iovs.11-9076

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 44

Metadata

Authors
Ye, X., Ren, H., Zhang, M., Sun, Z., Jiang, A. C., & Xu, G.
Affiliations
Shanghai Medical College of Fudan University (CN)
Corresponding author
  • Ye, Xiaofeng
  • Ren, Hui
  • Zhang, Meng
  • Sun, Zhongcui
  • Jiang, Alice C.
  • Xu, Gezhi
Venue
Investigative Opthalmology & Visual Science
Published
2012-06-08
Volume
53
Issue
7
Pages
3481
ISSN
  • 0146-0404 (ISSN-L)
  • 1552-5783
OpenAlex
W1963818413
Cited by
44
References
43
Citations by year
2026: 2 · 2025: 4 · 2024: 4 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 5 · 2018: 3 · 2017: 2 · 2016: 5 · 2015: 4 · 2014: 3 · 2013: 2 · 2012: 1
FWCI
2.99
Type
journal article
Language
en
Open access
closed
Locations
  • Investigative Ophthalmology & Visual Science (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
Keywords
ERK signaling, VEGF secretion, Müller cells, diabetic retinopathy, high glucose, AP-1 DNA binding, U0126, ERK1/2 phosphorylation, anti-VEGF therapy
MeSH terms
Animals, Butadienes, Diabetes Mellitus, Experimental, Diabetic Retinopathy, Enzyme Inhibitors, Enzyme-Linked Immunosorbent Assay, Glucose, Male, Neuroglia, Nitriles, Phosphorylation, Blotting, Western, Rats, Sprague-Dawley, Transcription Factor AP-1, Fluorescent Antibody Technique, Indirect, Mitogen-Activated Protein Kinase 1, MAP Kinase Signaling System, Electrophoretic Mobility Shift Assay, Vascular Endothelial Growth Factor A, Mitogen-Activated Protein Kinase 3, Rats, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.